1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pathology Analysis & Statistics 2020 - European Union

Pathology Analysis & Statistics 2020 - European Union

1-30 of about 400 reports

Hemophilia disease forecast and market analysis to 2035, Pharma Intelligence

  • $ 22000
  • July 2020
  • 86 pages

Disease Overview Hemophilia is a relatively rare hereditary genetic disorder characterized by an inability to produce a clot capable of stopping bleeding. Patients without hemophilia who develop inhibitors ...

  • Blood Disease
  • Pathology
  • European Union
  • United States
  • Forecast

Market Spotlight: Obesity

  • $ 1318
  • February 2020
  • 62 pages

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of ...

  • Obesity
  • Pathology
  • European Union

Stivarga

  • $ 10000
  • September 2019
  • 30 pages

Drug Overview Stivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently approved for the treatment of previously treated hepatocellular carcinoma patients. It ...

  • Cancer
  • Colorectal Cancer
  • Hepatitis
  • Pathology
  • European Union

Nexavar

  • $ 10000
  • September 2019
  • 28 pages

Drug Overview Nexavar (sorafenib; Bayer/Amgen) is an orally available, multi-targeted tyrosine kinase inhibitor that is directed against several targets, including CRAF, BRAF, RET, KIT, FMS-like tyrosine ...

  • Hepatitis
  • Pathology
  • Renal Cancer
  • European Union
  • United States

Lenvima

  • $ 10000
  • September 2019
  • 29 pages

Drug Overview Lenvima (lenvatinib; Eisai/Merck and Co) is an orally available small molecule inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived ...

  • Hepatitis
  • Pathology
  • Renal Cancer
  • European Union
  • Japan

Tecentriq

  • $ 10000
  • September 2019
  • 114 pages

Drug Overview Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Cancer
  • Pathology
  • European Union
  • United States
  • Demand

Opdivo

  • $ 10000
  • September 2019
  • 118 pages

Drug Overview Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Cyramza

  • $ 10000
  • September 2019
  • 65 pages

Drug Overview Cyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain ...

  • Cancer
  • Hepatitis
  • Pathology
  • European Union
  • Japan

Imfinzi

  • $ 10000
  • September 2019
  • 57 pages

Drug Overview Imfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), ...

  • Hepatitis
  • Lung Cancer
  • Pathology
  • European Union
  • Demand

Keytruda

  • $ 10000
  • September 2019
  • 141 pages

Drug Overview Keytruda (pembrolizumab; Merck and Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Cabometyx

  • $ 10000
  • September 2019
  • 29 pages

Drug Overview Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of ...

  • Hepatitis
  • Pathology
  • Renal Cancer
  • European Union
  • Supply

Nimenrix

  • $ 10000
  • September 2019
  • 13 pages

Drug Overview Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal ...

  • Meningococcal
  • Pathology
  • Vaccine
  • European Union
  • Market Description

MenABCW-135Y

  • $ 10000
  • September 2019
  • 12 pages

Drug Overview GlaxoSmithKline’s MenABCW-135Y is a pentavalent meningococcal conjugate vaccine for the A, B, C, W-135, and Y meningococcal strains. With all of the vaccine’s announced Phase II trials ...

  • Pathology
  • Vaccine
  • European Union
  • United States
  • Product Initiative

Menveo

  • $ 10000
  • September 2019
  • 12 pages

Drug Overview Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline) is a quadrivalent meningococcal glycoconjugate vaccine that uses CRM-197, a natural mutant of the ...

  • Meningococcal
  • Pathology
  • Vaccine
  • European Union
  • Forecast

Bexsero

  • $ 10000
  • September 2019
  • 13 pages

Drug Overview Bexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) is a multicomponent meningococcal serogroup B vaccine. It is approved for the prevention of invasive meningococcal ...

  • Meningococcal
  • Pathology
  • Vaccine
  • European Union
  • United States

Dovato

  • $ 10000
  • June 2019
  • 14 pages

Dovato ([dolutegravir + lamivudine]; ViiV Healthcare) is a single-tablet regimen approved in the US for the treatment of HIV-1 infection in patients who are treatment-naïve. It is also being developed ...

  • HIV AIDS
  • Pathology
  • Therapy
  • European Union
  • United States

Juluca

  • $ 10000
  • June 2019
  • 14 pages

Juluca ([dolutegravir + rilpivirine]; ViiV Healthcare/Johnson and Johnson) is a single-tablet regimen approved in the US for the treatment of patients infected with HIV-1 who have achieved viral supp ...

  • Antiviral
  • Pathology
  • Therapy
  • European Union
  • United States

leronlimab

  • $ 10000
  • June 2019
  • 14 pages

Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into ...

  • HIV AIDS
  • Medical Biotechnology
  • Pathology
  • European Union
  • United States

Stribild

  • $ 10000
  • June 2019
  • 16 pages

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed ...

  • Pathology
  • Therapy
  • European Union
  • Japan
  • United States

Tivicay

  • $ 10000
  • June 2019
  • 26 pages

Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.

  • HIV AIDS
  • Pathology
  • Therapy
  • European Union
  • United States

Complera

  • $ 10000
  • June 2019
  • 15 pages

Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson and Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.

  • HIV AIDS
  • Pathology
  • Therapy
  • European Union
  • United States

Atripla

  • $ 10000
  • June 2019
  • 14 pages

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

  • HIV AIDS
  • Pathology
  • Therapy
  • European Union
  • United States

Isentress

  • $ 10000
  • June 2019
  • 14 pages

Isentress (raltegravir; Merck and Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.

  • HIV Antiviral
  • Pathology
  • Therapy
  • European Union
  • United States

Genvoya

  • $ 10000
  • June 2019
  • 15 pages

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.

  • Hepatitis Treatment
  • Pathology
  • Therapy
  • European Union
  • United States

Seroquel/Seroquel XR, Pharma Intelligence

  • $ 10000
  • March 2019
  • 48 pages

The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic ...

  • Bipolar Disorder
  • Mental Health
  • Pathology
  • Psychotic Disorder
  • European Union

Rexulti

  • $ 10000
  • March 2019
  • 33 pages

Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; ...

  • Depression
  • Mental Health
  • Pathology
  • Psychotic Disorder
  • European Union

Cymbalta

  • $ 10000
  • March 2019
  • 25 pages

Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since ...

  • Chronic Pain
  • Depression
  • Pathology
  • European Union
  • United States

Abilify/Abilify Maintena, Pharma Intelligence

  • $ 10000
  • March 2019
  • 62 pages

Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A ...

  • Mental Health
  • Pathology
  • Psychotic Disorder
  • European Union
  • Japan

Votrient

  • $ 10000
  • March 2019
  • 21 pages

Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical ...

  • Cancer
  • Pathology
  • Renal Cancer
  • European Union
  • Japan

Torisel

  • $ 10000
  • March 2019
  • 24 pages

Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.

  • Cancer
  • Lymphoma
  • Pathology
  • Renal Cancer
  • European Union

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on